Methods of treating ocular diseases using aav2 variants encoding aflibercept
AssigneeAdverum Biotechnologies, Inc.
InventorsJulie CLARK, Scott WHITCUP, Adam TURPCU
Life of this patent
Estimating the term…
Loading patent…
AssigneeAdverum Biotechnologies, Inc.
InventorsJulie CLARK, Scott WHITCUP, Adam TURPCU
Estimating the term…
Provided are methods for treating an ocular disease in an individual, comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to an eye of the individual, wherein the rAAV particles comprise: a) a nucleic acid encoding a polypeptide comprising an amino acid sequence with at least about 95% identity to the amino acid sequence of SEQ ID NO: 35 and flanked by AAV2 inverted terminal repeats (ITRs), and b) an AAV2 capsid protein comprising an amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to an AAV2 VP1 capsid protein.
A method for treating glaucoma in an individual, the method comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to one eye of the individual, wherein the individual is a human, and wherein the rAAV particles comprise
A method for reducing intraocular pressure in an individual, the method comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to one eye of the individual, wherein the individual is a human, and wherein the rAAV particles comprise
a A method of reducing intraocular pressure in an individual, the method comprising administering a unit dose of rAAV particles to one eye of the individual, wherein the individual is a human, and wherein the rAAV particles comprise
A unit dose of about 6×1011 vector genomes (vg) or less of recombinant adeno-associated virus (rAAV) particles for use in a method for treating glaucoma in an individual, the method comprising administering said unit dose to one eye of the individual, wherein the individual is a human, and wherein the rAAV particles comprise:
A unit dose of rAAV particles for use in a method for reducing intraocular pressure in an eye of an individual in need thereof, the method comprising administering said unit dose to one eye of the individual, wherein the individual is a human, and wherein the rAAV particles comprise:
Dependencies are inferred from the claim text.